MMR Information Systems, Sanofi-aventis Sign Agreement For Anti-CD20 Monoclonal Antibodies

MMR said that these antibody assets may be used in the development of future treatment options for various autoimmune and B-Cell mediated diseases, which could include lupus nephritis, systemic lupus erythematosus, psoriasis, inflammatory bowel disease, respiratory distress syndrome, chronic lymphocytic leukemia, multiple sclerosis and vaculitis.

Bruce Garrett, president and chief operating officer of GRSworldwide (GRS) of biotech consultants on its anti-CD20 antibody assets at MMR based in Maryland, said: “These assets could show promise for treating a variety of medical conditions, chief among them cancer, rheumatoid arthritis and potentially others. Based on existing data, GRS believes this particular formulary has the potential to become one of the best anti-CD20 monoclonal antibodies in its class.”

Robert Lorsch, chairman and CEO of MMR Information Systems, said: “Our primary business is the development, marketing and sales of the company’s personal and professional health IT products, however, maximising shareholder value is always a primary focus.

“It now appears that monetizing pre-merger assets such as the anti-CD20 antibodies and licensing the use of clinical trials data and patient samples from FavId trials, may represent a unique opportunity to generate shareholder value that was not contemplated as part of the Company’s original post-merger business plan, particularly in the area of cancer research.”